Related Experiment Video
Updated: Aug 5, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
Giant cell (temporal) arteritis-polymyalgia rheumatica: a critical review
1Ipswich Hospitals, Suffolk.
Insights
Giant cell (temporal) arteritis is a common inflammatory condition affecting large arteries in individuals over 50. This review highlights controversies and neglected aspects, including its potential underdiagnosis and involvement of intracerebral vessels.
Area of Science:
- Rheumatology
- Vascular Medicine
- Epidemiology
Background:
- Giant cell (temporal) arteritis (GCA) is a prevalent vasculitis affecting medium and large arteries.
- Up to 50% of polymyalgia rheumatica (PMR) patients may develop GCA manifestations.
- GCA diagnosis can be challenging, with potential for underdiagnosis.
Purpose of the Study:
- To critically review controversial and neglected aspects of Giant Cell Arteritis.
- To emphasize the need for urgent clarification on intracerebral vessel involvement.
- To highlight the implications of symptomatically silent but active GCA.
Main Methods:
- Critical literature review.
- Analysis of epidemiological data, including autopsy statistics.
- Discussion of clinical implications and diagnostic challenges.
Main Results:
- Autopsy data suggest GCA is more common than clinically diagnosed.
- Uncertainty persists regarding intracerebral vessel involvement in GCA.
- GCA can be active and asymptomatic, posing diagnostic difficulties.
Conclusions:
- GCA diagnosis and management require further research into epidemiology and vessel involvement.
- Clinicians must consider the possibility of silent GCA, especially in at-risk populations.
- Urgent research is needed to address diagnostic gaps and treatment implications, particularly concerning stroke management.
Abstract:
Giant cell (temporal) arteritis G.C.(T) A. is common disorder and affects medium sized and large arteries in people over the age of fifty. Many series show that up to 50% of people with the clinical syndrome of polymyalgia rheumatica (PMR) go on to develop manifestations of G.C.(T) A. within a year; others may do so later. A critical review is offered of aspects of the subject which despite much study and research remain controversial or neglected. This includes epidemiology: statistics from routine autopsy suggests that the disease affects more people than are diagnosed clinically. The need to resolve uncertainty whether intracerebral vessels are involved or not, is now urgent, particularly in view of the wide spread use of short courses of Dexamethasone in the treatment of stroke. All clinicians should recognise the implications of the fact that they are dealing with a disease which may be active and yet symptomatically silent.
Related Concept Videos
Myocarditis II: Clinical Features and Diagnostic Tests
Pericarditis III: Medical Management
Rheumatic Heart Disease I: Introduction
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease III: Medical Management
Chronic Inflammation: Introduction

